查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1379987

勝肽抗生素市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按類型、給藥途徑、配銷通路、地區和競爭細分

Peptide Antibiotics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Type, by Route of Administration, by Distribution Channel, by region, and Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球勝肽類抗生素市場價值達 49 億美元，預計到 2028 年，複合CAGR將達到 6.35%。肽類抗生素是一類由短鏈氨基組成的抗菌化合物。酸，蛋白質的組成部分。這些勝肽可以抑制細菌和其他微生物的生長和繁殖，使其能夠有效治療各種感染性疾病。勝肽抗生素與傳統的小分子抗生素不同，因為它們由較大的蛋白質樣分子組成。肽抗生素由相對較短的氨基酸鏈組成，通常為幾個到幾十個氨基酸殘基。這些勝肽的結構可以是線性或環狀的。肽類抗生素透過多種機制發揮抗菌作用。有些會破壞細菌細胞膜，導致其破裂。另一些則干擾重要的細胞過程，例如蛋白質合成、DNA 複製或細胞壁合成。機制的多樣性使得細菌難以產生抗藥性。

主要市場促進因素

市場概況
預測期 2024-2028
2022 年市場規模 49億美元
2028 年市場規模 71億美元
2023-2028 年CAGR 6.35%
成長最快的細分市場 可注射
最大的市場 北美洲

肽合成的進展

固相勝肽合成徹底改變了勝肽的生產。它允許將勝肽構建在固體支撐物上，簡化純化並實現自動化。樹脂和連接體技術的發展提高了SPPS的速度和效率。肽合成的自動化已成為許多實驗室和生產設施的標準。自動化合成儀能夠精確控制反應條件和複雜勝肽的合成。 Fmoc（9-芴甲氧基羰基）和Boc（叔丁氧基羰基）保護基的引入使得勝肽合成更通用和高效。基於 Fmoc 的 SPPS 目前是最廣泛使用的方法，因為它與自動合成和較溫和的去保護條件相容。

勝肽組裝策略的進步，例如一鍋或多段合成，簡化了長肽或複雜勝肽的合成。正交保護基團的開發允許特定官能基的選擇性脫保護，從而增強具有挑戰性的勝肽的合成。連續流肽合成系統已經出現，能夠快速且有效率地生產勝肽。流動化學可以精確控制反應條件，並且可以輕鬆擴大規模以進行大規模合成。天然化學連接和表達蛋白連接等方法可以合成更長、更複雜的勝肽甚至蛋白質片段。這些技術對於生產更大的治療性勝肽至關重要。固相支持物上勝肽庫的高通量篩選透過更有效地識別先導化合物加速了藥物發現。色譜和質譜技術的進步改進了合成勝肽的純化和表徵。將勝肽與其他分子（例如脂質、蛋白質或奈米顆粒）綴合的技術擴大了勝肽在藥物傳遞和診斷中的應用。透過各種策略（例如二硫鍵形成或裝訂）對勝肽進行環化，可增強其穩定性和生物活性。這一因素將有助於全球肽抗生素市場的發展。

抗生素抗藥性上升

當細菌形成抵抗抗生素作用的機制時，就會出現抗生素抗藥性，使這些藥物在治療細菌感染方面效果較差或完全無效。這場全球健康危機迫切需要新型創新抗生素。勝肽抗生素通常具有與傳統抗生素不同的新穎作用機制。這些機制可以使細菌難以快速產生抗藥性，使得勝肽類抗生素在對抗抗藥性菌株方面具有重要價值。一些勝肽抗生素具有廣譜活性，這意味著它們可以針對多種細菌病原體。在處理各種抗藥性細菌引起的感染時，這種多功能性至關重要。肽類抗生素不太可能與現有抗生素產生交叉抗藥性。針對傳統抗生素的細菌抗藥性機制可能對勝肽無效。肽抗生素可以同時針對多種重要的細菌功能，這使得細菌很難透過單一突變產生抗藥性。勝肽抗生素通常對細菌細胞具有高度特異性，最大限度地減少對人體細胞的附帶損害並降低副作用的風險。

研究人員可以探索涉及勝肽抗生素和傳統抗生素的聯合療法，以提高療效並降低抗藥性的可能性。一些勝肽類抗生素已在治療抗藥性感染方面表現出臨床有效性，增強了其臨床實踐價值。正在進行的研究工作重點是發現具有改進特性的新型勝肽抗生素，包括增強效力、穩定性和降低毒性。醫療機構正在實施抗生素管理計劃，以確保負責任地使用抗生素，包括在需要時使用勝肽抗生素等新型抗生素。流行病等全球健康威脅的出現凸顯了有效抗生素（包括勝肽抗生素）治療繼發性細菌感染的重要性。監管機構意識到迫切需要針對抗藥性感染的有效治療方法，因此願意簡化新型抗生素的核准流程。臨床環境中對抗生素，特別是對抗藥性病原體有效的抗生素的需求仍然很高，這推動了對勝肽抗生素的市場需求。這項因素將加快全球勝肽抗生素市場的需求。

老年人口不斷增加

老化往往伴隨著免疫系統減弱，使老年人更容易受到感染。他們罹患肺炎、泌尿道感染和皮膚感染等細菌感染的風險較高，可能需要抗生素治療，包括勝肽類抗生素。許多老年人患有一種或多種慢性健康狀況，例如糖尿病、心血管疾病或呼吸系統疾病。這些情況會增加感染的風險，可能需要抗生素來控制或治療與這些疾病相關的感染。居住在長期照護機構或療養院的長者可能面臨更高的醫療相關感染風險。勝肽抗生素對於治療和預防這個弱勢族群的感染非常重要。老年人可能會接受手術來解決與年齡相關的健康問題，術後感染是一個問題。在這些情況下，可以使用抗生素，包括勝肽抗生素來預防或治療。

老年人通常有複雜的醫療保健需求，包括多種藥物和合併症。這種複雜性會增加​​藥物交互作用的風險，並需要使用抗生素來治療感染。肺炎和支氣管炎等呼吸道感染在老年人中很常見，可能需要抗生素治療。一些勝肽抗生素已被證明對呼吸道病原體有效。體弱的老年人更有可能住院治療，因為他們可能會接觸抗抗生素的病原體。有效的抗生素，例如勝肽抗生素，對於控制這些感染至關重要。由於不良反應和藥物交互作用的風險，因此對老年人謹慎使用抗生素至關重要。具有特定作用機制的勝肽抗生素可能是優選的，以盡量減少潛在的副作用。研究人員擴大研究抗生素（包括勝肽抗生素）在老年人群中的安全性和有效性，以確保適當的劑量和治療指南。隨著預期壽命的延長，越來越多的人達到了可能需要抗生素治療各種感染的年齡，這進一步增加了對抗生素的需求。這項因素將加速全球肽類抗生素市場的需求。

主要市場挑戰

開發成本高

肽抗生素的開發始於廣泛的研究，以確定有前途的化合物及其作用機制。臨床前測試涉及體外和動物研究以評估安全性和有效性。這些早期階段需要大量資金用於研究人員、實驗室設施和動物照護。臨床試驗是開發過程中至關重要的一步。它們涉及對人體進行嚴格的測試以評估安全性和有效性。臨床試驗分為幾個階段，每個階段都會增加整體成本。 III 期試驗涉及大量患者，費用可能特別昂貴。滿足美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等機構制定的監管要求是一個成本高且耗時的過程。開發人員必須進行研究並收集大量資料，以證明安全性和有效性，並符合品質標準。擴大勝肽抗生素的生產用於臨床試驗和最終商業化是一筆巨大的開支。在大規模生產過程中保持一致的品質和純度至關重要，並且會增加成本。嚴格的品質控制和保證流程對於確保勝肽抗生素符合安全性和有效性標準至關重要。這些過程需要對專業人員、設備和基礎設施進行投資。取得和維護新型勝肽抗生素的專利可能成本高昂，但對於保護研發投資至關重要。臨床支持，包括監測病人安全和收集資料，增加了臨床試驗的成本。持續監控對於確保產品的安全性和有效性至關重要。

有限的目標頻譜

許多勝肽抗生素對特定的細菌亞群或特定類型的感染有效。這種有限的目標範圍意味著它們可能不適合治療廣泛的細菌感染，包括由目標範圍之外的細菌引起的感染。在臨床實踐中，醫療保健提供者確定引起感染的確切細菌病原體可能具有挑戰性。如果肽類抗生素的目標譜較窄，則可能無法覆蓋導致感染的特定病原體，從而導致治療失敗。醫療保健提供者必須準確診斷感染細菌，以選擇最合適的抗生素。肽類抗生素的標靶光譜有限，可能會導致其在無效的情況下使用不當，從而導致抗藥性的產生。為了解決窄標靶的挑戰，勝肽抗生素可能需要與其他抗生素合併使用。這會增加治療方案的複雜性和不良反應的風險。窄譜勝肽抗生素的臨床應用可能有限，特別是在由於診斷不確定性或混合感染的可能性而可能優選更廣譜抗生素的情況下。肽抗生素市場面臨其他抗生素的競爭，其中一些抗生素具有更廣泛的活性。這種競爭可能會影響勝肽抗生素的採用，特別是在選擇治療方案時。

主要市場趨勢

人們對抗菌肽 (AMP) 的認知不斷增強

AMP 是在各種生物體中發現的天然分子，包括人類、動物、植物和微生物。它們來源的多樣性為發現具有獨特性質的新 AMP 提供了機會。 AMP 通常表現出廣泛的抗菌活性，這意味著它們可以針對多種細菌、真菌、病毒，甚至寄生蟲。這種多功能性對於對抗各種傳染源非常有價值。 AMP 的作用機轉與傳統抗生素不同，這使得微生物難以快速產生抗藥性。這在抗生素抗藥性不斷上升的背景下尤其重要。有些 AMP 具有免疫調節功能，包括調節宿主免疫反應的能力。此功能有助於控制感染和發炎。 AMP 可與傳統抗生素合併使用，以增強其有效性並降低抗藥性風險。這種方法正在探索治療多重抗藥性感染。某些 AMP 具有傷口癒合特性，可促進組織修復和再生。它們用於各種醫療應用，包括傷口敷料和護膚產品。製藥和生物技術公司正在投資基於 AMP 的療法的開發和商業化，這進一步推動了人們對該領域的認知和興趣。在某些情況下，AMP 被認為是傳統抗生素的替代品，特別是在治療由多重抗藥性或難以治療的病原體引起的感染時。

細分市場洞察

類型洞察

2022年，全球勝肽類抗生素市場最大佔有率由非核醣體合成勝肽類抗生素領域佔據，預計未來幾年將繼續擴大。非核醣體合成勝肽抗生素通常具有獨特的作用機制，使其能夠有效對抗多種細菌，包括抗生素抗藥性菌株。這種多功能性有助於提高它們的受歡迎程度和市場佔有率。一些非核醣體合成勝肽抗生素在治療具有挑戰性的細菌感染方面表現出很高的臨床療效，從而導致其廣泛使用和採用。非核醣體合成勝肽抗生素可能不太容易受到影響傳統抗生素的某些抗藥性機制的影響，這使得它們在增加抗生素抗藥性的背景下很有價值。某些非核醣體合成勝肽抗生素用於專門的醫療環境，例如治療醫療機構中的特定感染或免疫功能低下的患者。這可以推動對這些產品的需求。

管理途徑見解

2022年，全球勝肽抗生素市場最大佔有率由注射給藥途徑佔據，預計未來幾年將繼續擴大。通常選擇勝肽抗生素的注射製劑，因為它們提供了一種可靠且有效的方式將藥物直接輸送到血液中。這確保了藥物的快速和一致吸收，使其在治療嚴重細菌感染方面非常有效。肽抗生素通常用於治療嚴重且危及生命的感染，例如敗血症、肺炎以及某些類型的皮膚和軟組織感染。在這種情況下，優選注射製劑以確保立即發揮治療作用。由於受控環境和密切監測患者的能力，醫院和醫療機構經常使用注射藥物。當處理需要及時治療的危重患者時，這一點尤其重要。

配銷通路洞察

2022年，全球肽類抗生素市場最大佔有率由醫院藥房部門佔據，預計未來幾年將繼續擴大。肽抗生素通常用於治療嚴重且危及生命的感染，這些感染通常需要住院治療。醫院藥局在醫療機構內供應和管理這些藥物的分配方面發揮著至關重要的作用。醫院通常儲備多種藥物，包括勝肽抗生素等專門抗生素，以滿足患者的需求。醫院藥房設備齊全，可以安全有效地儲存和分發這些藥物。許多勝肽抗生素透過靜脈注射給藥，這在醫院環境中很常見。醫院藥房負責配製和製備這些抗生素的靜脈注射製劑，確保劑量準確和無菌。

區域洞察

北美地區將在 2022 年主導全球勝肽抗生素市場。北美，尤其是美國，一直是全球醫療保健支出水準最高的地區之一。這筆巨額醫療保健支出用於支持藥物（包括勝肽抗生素）的研發、製造和分銷。該地區擁有發達的醫療基礎設施，包括世界一流的醫院、研究機構和製藥公司。該基礎設施促進了藥品的開發、生產和分銷。北美是藥物研究和創新的中心。它是許多生物技術和製藥公司的所在地，這些公司大力投資開發新型藥物，包括勝肽抗生素。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球勝肽類抗生素市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依類型（非核醣體合成勝肽抗生素、核醣體合成勝肽抗生素）
    • 依給藥途徑（注射、口服、局部）
    • 按配銷通路（醫院藥房、網路藥房和零售藥房）
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：亞太地區勝肽類抗生素市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國勝肽抗生素
    • 印度勝肽抗生素
    • 澳洲勝肽抗生素
    • 日本勝肽抗生素
    • 韓國勝肽抗生素

第 7 章：歐洲勝肽類抗生素市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章：北美勝肽類抗生素市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 9 章：南美洲勝肽類抗生素市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章 ：中東和非洲勝肽類抗生素市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 依給藥途徑
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非勝肽抗生素
    • 沙烏地阿拉伯勝肽抗生素
    • 阿拉伯聯合大公國勝肽抗生素

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：全球勝肽抗生素市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第 15 章：大環境分析

第16章：競爭格局

  • 輝瑞公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 默克公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 艾伯維公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 葛蘭素史克集團公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 山德士國際有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 塞利亞製藥公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • AuroMedics 製藥股份有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
  • 葛蘭素史克公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
    • SWOT Analysis
  • 梯瓦製藥工業股份有限公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
    • SWOT Analysis
  • 諾華公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Financials (In case of listed companies)
    • Recent Developments
    • SWOT Analysis
    • SWOT Analysis

第 17 章：策略建議

第 18 章：關於我們與免責聲明

簡介目錄
Product Code: 16968

Global Peptide Antibiotics Market has valued at USD 4.90 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.35% through 2028. Peptide antibiotics are a class of antimicrobial compounds that are made up of short chains of amino acids, the building blocks of proteins. These peptides can inhibit the growth and reproduction of bacteria and other microorganisms, making them effective in the treatment of various infectious diseases. Peptide antibiotics are distinct from traditional small-molecule antibiotics in that they are composed of larger, protein-like molecules. Peptide antibiotics consist of relatively short chains of amino acids, typically ranging from a few to several dozen amino acid residues. These peptides can be linear or cyclic in structure. Peptide antibiotics exert their antimicrobial effects through a variety of mechanisms. Some disrupt the bacterial cell membrane, causing it to rupture. Others interfere with essential cellular processes, such as protein synthesis, DNA replication, or cell wall synthesis. The diversity of mechanisms makes it challenging for bacteria to develop resistance.

Peptide antibiotics can have broad-spectrum activity, meaning they are effective against a wide range of bacterial species, or narrow-spectrum activity, targeting specific types of bacteria. The specificity of action can vary among different peptide antibiotics. The increasing prevalence of antibiotic-resistant bacteria is a significant driver for the development and use of peptide antibiotics. These antibiotics often have unique mechanisms of action that can overcome resistance. The aging population is more susceptible to infections, making the development and use of effective antibiotics crucial. Peptide antibiotics can be particularly useful in this context. Technological advances in peptide synthesis have made it more cost-effective and efficient to produce peptide antibiotics, contributing to market growth. Healthcare institutions are implementing antibiotic stewardship programs to optimize the use of antibiotics, ensuring they are used responsibly and judiciously. Surgical procedures often require prophylactic antibiotic use to prevent postoperative infections, creating demand for effective antibiotics, including peptide antibiotics.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 4.90 Billion
Market Size 2028USD 7.10 Billion
CAGR 2023-20286.35%
Fastest Growing SegmentInjectable
Largest MarketNorth America

Advancements in Peptide Synthesis

Solid-phase peptide synthesis revolutionized peptide production. It allows peptides to be built on a solid support, simplifying purification, and enabling automation. The development of resin and linker technologies has improved the speed and efficiency of SPPS. Automation of peptide synthesis has become standard in many laboratories and production facilities. Automated synthesizers enable precise control of reaction conditions and the synthesis of complex peptides. The introduction of Fmoc (9-fluorenylmethyloxycarbonyl) and Boc (tert-butyloxycarbonyl) protecting groups has made peptide synthesis more versatile and efficient. Fmoc-based SPPS is now the most widely used method due to its compatibility with automated synthesis and milder deprotection conditions.

Advances in peptide assembly strategies, such as one-pot or multi-segment synthesis, have simplified the synthesis of long or complex peptides. The development of orthogonal protecting groups allows for the selective deprotection of specific functional groups, enhancing the synthesis of challenging peptides. Continuous-flow peptide synthesis systems have emerged, enabling rapid and efficient peptide production. Flow chemistry offers precise control over reaction conditions and can be easily scaled up for large-scale synthesis. Methods like native chemical ligation and expressed protein ligation enable the synthesis of longer and more complex peptides and even protein fragments. These techniques have been crucial in producing larger therapeutic peptides. High-throughput screening of peptide libraries on solid supports has accelerated drug discovery by identifying lead compounds more efficiently. Advances in chromatography and mass spectrometry techniques have improved the purification and characterization of synthetic peptides. Techniques for conjugating peptides to other molecules, such as lipids, proteins, or nanoparticles, have expanded the applications of peptides in drug delivery and diagnostics. Cyclization of peptides through various strategies, such as disulfide bond formation or stapling, enhances their stability and bioactivity. This factor will help in the development of the Global Peptide Antibiotics Market.

Rising Antibiotic Resistance

Antibiotic resistance occurs when bacteria develop mechanisms to withstand the effects of antibiotics, rendering these drugs less effective or completely ineffective in treating bacterial infections. This global health crisis has created a pressing need for new and innovative antibiotics. Peptide antibiotics often have novel mechanisms of action that are distinct from traditional antibiotics. These mechanisms can make it difficult for bacteria to develop resistance quickly, making peptide antibiotics valuable in the fight against drug-resistant strains. Some peptide antibiotics exhibit a broad spectrum of activity, meaning they can target a wide range of bacterial pathogens. This versatility is essential when dealing with infections caused by various resistant bacteria. Peptide antibiotics are less likely to face cross-resistance with existing antibiotics. Bacterial resistance mechanisms that work against conventional antibiotics may not be effective against peptides. Peptide antibiotics can target multiple essential bacterial functions simultaneously, making it challenging for bacteria to develop resistance through single mutations. Peptide antibiotics often have high specificity for bacterial cells, minimizing collateral damage to human cells and reducing the risk of side effects.

Researchers can explore combination therapies that involve peptide antibiotics and traditional antibiotics to enhance efficacy and reduce the likelihood of resistance. Some peptide antibiotics have demonstrated clinical effectiveness in treating drug-resistant infections, reinforcing their value in clinical practice. Ongoing research efforts are focused on discovering new peptide antibiotics with improved properties, including enhanced potency, stability, and reduced toxicity. Healthcare institutions are implementing antibiotic stewardship programs to ensure responsible antibiotic use, including the use of newer antibiotics like peptide antibiotics when needed. The emergence of global health threats, such as pandemics, has highlighted the importance of effective antibiotics, including peptide antibiotics, to treat secondary bacterial infections. Regulatory agencies have shown willingness to streamline the approval process for novel antibiotics, recognizing the urgent need for effective treatments against resistant infections. The demand for antibiotics, especially those effective against resistant pathogens, remains high in clinical settings, contributing to the market demand for peptide antibiotics. This factor will pace up the demand of the Global Peptide Antibiotics Market.

Growing Geriatric Population

Aging is often accompanied by a weakened immune system, making older adults more vulnerable to infections. They are at higher risk for bacterial infections such as pneumonia, urinary tract infections, and skin infections, which may require antibiotic treatment, including peptide antibiotics. Many older adults have one or more chronic health conditions, such as diabetes, cardiovascular disease, or respiratory disorders. These conditions can increase the risk of infections, and antibiotics may be needed to manage or treat infections associated with these diseases. Older adults residing in long-term care facilities or nursing homes may be at higher risk for healthcare-associated infections. Peptide antibiotics can be important for treating and preventing infections in this vulnerable population. Older adults may undergo surgeries to address age-related health issues, and postoperative infections are a concern. Antibiotics, including peptide antibiotics, may be used prophylactically or therapeutically in these cases.

Older adults often have complex healthcare needs, including multiple medications and comorbidities. This complexity can increase the risk of drug interactions and necessitate the use of antibiotics for infections. Respiratory infections, such as pneumonia and bronchitis, are common among older adults and may require antibiotic treatment. Some peptide antibiotics have demonstrated effectiveness against respiratory pathogens. Frail older adults are more likely to experience hospitalizations, where they may be exposed to antibiotic-resistant pathogens. Effective antibiotics, such as peptide antibiotics, are essential in managing these infections. Due to the risk of adverse effects and drug interactions, it's crucial to use antibiotics judiciously in older adults. Peptide antibiotics with specific mechanisms of action may be preferred to minimize potential side effects. Researchers are increasingly studying the safety and efficacy of antibiotics, including peptide antibiotics, in geriatric populations to ensure appropriate dosing and treatment guidelines. As life expectancy increases, more people are reaching an age where they may require antibiotic treatment for various infections, further contributing to the demand for antibiotics. This factor will accelerate the demand of the Global Peptide Antibiotics Market.

Key Market Challenges

High Development Costs

The development of a peptide antibiotic begins with extensive research to identify promising compounds and their mechanisms of action. Preclinical testing involves in vitro and animal studies to assess safety and efficacy. These early stages require substantial funding for research personnel, laboratory facilities, and animal care. Clinical trials are a crucial step in the development process. They involve rigorous testing in human subjects to evaluate safety and effectiveness. Clinical trials are divided into phases, with each phase adding to the overall cost. Phase III trials, which involve large patient populations, can be especially expensive. Meeting regulatory requirements set by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is a costly and time-consuming process. Developers must conduct studies and gather extensive data to demonstrate safety and efficacy, as well as meet quality standards. Scaling up the production of peptide antibiotics for clinical trials and eventual commercialization is a significant expense. Maintaining consistent quality and purity during large-scale manufacturing is crucial and adds to the cost. Stringent quality control and assurance processes are essential to ensure that peptide antibiotics meet safety and efficacy standards. These processes require investment in specialized personnel, equipment, and infrastructure. Securing and maintaining patents for new peptide antibiotics can be expensive and is crucial for protecting investments in research and development. Clinical support, including monitoring patient safety and collecting data, adds to the cost of clinical trials. Ongoing monitoring is essential to ensure the product's safety profile and efficacy.

Limited Target Spectrum

Many peptide antibiotics are effective against a specific subset of bacteria or a particular type of infection. This limited target spectrum means that they may not be suitable for treating a broad range of bacterial infections, including those caused by bacteria outside their target range. In clinical practice, it can be challenging for healthcare providers to determine the exact bacterial pathogen causing an infection. If a peptide antibiotic has a narrow target spectrum, it may not cover the specific pathogen responsible for the infection, leading to treatment failure. Healthcare providers must accurately diagnose the infecting bacteria to choose the most appropriate antibiotic. The limited target spectrum of peptide antibiotics may lead to their inappropriate use in cases where they are not effective, contributing to the development of resistance. To address the challenge of a narrow target spectrum, peptide antibiotics may need to be used in combination with other antibiotics. This can increase the complexity of treatment regimens and the risk of adverse effects. Peptide antibiotics with a narrow spectrum may have limited clinical applications, particularly in settings where a broader spectrum antibiotic may be preferred due to diagnostic uncertainties or the potential for mixed infections. The peptide antibiotics market faces competition from other antibiotics, some of which have broader spectra of activity. This competition can affect the adoption of peptide antibiotics, particularly when selecting treatment options.

Key Market Trends

Growing Awareness of Antimicrobial Peptides (AMPs)

AMPs are naturally occurring molecules found in various organisms, including humans, animals, plants, and microorganisms. Their diversity in sources presents opportunities for the discovery of new AMPs with unique properties. AMPs typically exhibit a broad spectrum of antimicrobial activity, meaning they can target a wide range of bacteria, fungi, viruses, and even parasites. This versatility is valuable in combating various infectious agents. AMPs have mechanisms of action that differ from traditional antibiotics, making it challenging for microorganisms to develop resistance quickly. This is particularly important in the context of rising antibiotic resistance. Some AMPs possess immunomodulatory functions, including the ability to modulate the host's immune response. This feature can be beneficial in managing infections and inflammation. AMPs can be used in combination with traditional antibiotics to enhance their effectiveness and reduce the risk of resistance. This approach is being explored in the treatment of multidrug-resistant infections. Certain AMPs have wound-healing properties, promoting tissue repair and regeneration. They are used in various medical applications, including wound dressings and skincare products. Pharmaceutical and biotechnology companies are investing in the development and commercialization of AMP-based therapies, which is driving further awareness and interest in this field. In some cases, AMPs are considered an alternative to traditional antibiotics, especially when treating infections caused by multidrug-resistant or difficult-to-treat pathogens.

Segmental Insights

Type Insights

In 2022, the Global Peptide Antibiotics Market largest share was held by non-ribosomal synthesized peptide antibiotics segment and is predicted to continue expanding over the coming years. Non-ribosomal synthesized peptide antibiotics often have unique mechanisms of action that make them effective against a broad spectrum of bacteria, including antibiotic-resistant strains. This versatility can contribute to their popularity and market share. Some non-ribosomal synthesized peptide antibiotics have demonstrated high clinical efficacy in treating challenging bacterial infections, leading to their widespread use and adoption. Non-ribosomal synthesized peptide antibiotics may be less susceptible to certain resistance mechanisms that affect traditional antibiotics, making them valuable in the context of increasing antibiotic resistance. Certain non-ribosomal synthesized peptide antibiotics are used in specialized medical settings, such as the treatment of specific infections in healthcare settings or immunocompromised patients. This can drive demand for these products.

Route of Administration Insights

In 2022, the Global Peptide Antibiotics Market largest share was held by injectable route of administration segment and is predicted to continue expanding over the coming years. Injectable formulations of peptide antibiotics are often chosen because they offer a reliable and efficient way to deliver the medication directly into the bloodstream. This ensures rapid and consistent drug absorption, making them highly effective in treating serious bacterial infections. Peptide antibiotics are frequently used to treat severe and life-threatening infections, such as sepsis, pneumonia, and certain types of skin and soft tissue infections. In such cases, injectable formulations are preferred to ensure immediate therapeutic action. Hospitals and healthcare facilities often administer injectable medications due to the controlled environment and the ability to closely monitor patients. This is especially important when dealing with critically ill patients who require prompt treatment.

Distribution Channel Insights

In 2022, the Global Peptide Antibiotics Market largest share was held by hospital pharmacies segment in the forecast period and is predicted to continue expanding over the coming years. Peptide antibiotics are often used to treat serious and life-threatening infections, which frequently require hospitalization. Hospital pharmacies play a crucial role in supplying and managing the distribution of these medications within healthcare facilities. Hospitals typically stock a wide range of medications, including specialized antibiotics like peptide antibiotics, to meet the needs of their patients. Hospital pharmacies are well-equipped to store and dispense these medications safely and efficiently. Many peptide antibiotics are administered intravenously, which is common in hospital settings. Hospital pharmacies are responsible for compounding and preparing IV formulations of these antibiotics, ensuring accurate dosing and sterility.

Regional Insights

The North America region dominates the Global Peptide Antibiotics Market in 2022. North America, particularly the United States, has historically had one of the highest healthcare expenditure levels globally. This substantial healthcare spending supports research and development, manufacturing, and distribution of pharmaceuticals, including peptide antibiotics. The region boasts a well-developed healthcare infrastructure, including world-class hospitals, research institutions, and pharmaceutical companies. This infrastructure facilitates the development, production, and distribution of pharmaceutical products. North America is a hub for pharmaceutical research and innovation. It is home to numerous biotechnology and pharmaceutical companies that invest heavily in developing novel medications, including peptide antibiotics.

Key Market Players

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AbbVie Inc
  • GSK Group of Companies
  • Sandoz International GmbH
  • Novartis AG
  • Xellia Pharmaceuticals
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • AuroMedics Pharma LLC

Report Scope:

In this report, the Global Peptide Antibiotics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Antibiotics Market, By Type:

  • Non-Ribosomal Synthesized Peptide Antibiotics
  • Ribosomal Synthesized Peptide Antibiotics

Peptide Antibiotics Market, By Route of Administration:

  • Injectable
  • Oral
  • Topical

Peptide Antibiotics Market, By Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Global Peptide Antibiotics Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Peptide Antibiotics Market.

Available Customizations:

  • Global Peptide Antibiotics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Antibiotics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Non-Ribosomal Synthesized Peptide Antibiotics, Ribosomal Synthesized Peptide Antibiotics)
    • 5.2.2. By Route of Administration (Injectable, Oral, Topical)
    • 5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy & Retail Pharmacy)
    • 5.2.4. By Company (2022)
  • 5.3. Market Map

6. Asia Pacific Peptide Antibiotics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Peptide Antibiotics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. India Peptide Antibiotics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Australia Peptide Antibiotics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Japan Peptide Antibiotics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Type
        • 6.3.4.2.2. By Route of Administration
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. South Korea Peptide Antibiotics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Type
        • 6.3.5.2.2. By Route of Administration
        • 6.3.5.2.3. By Distribution Channel

7. Europe Peptide Antibiotics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Peptide Antibiotics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Germany Peptide Antibiotics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Spain Peptide Antibiotics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Peptide Antibiotics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. United Kingdom Peptide Antibiotics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Distribution Channel

8. North America Peptide Antibiotics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Peptide Antibiotics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Mexico Peptide Antibiotics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Canada Peptide Antibiotics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Distribution Channel

9. South America Peptide Antibiotics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Peptide Antibiotics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Peptide Antibiotics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Peptide Antibiotics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Peptide Antibiotics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Peptide Antibiotics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Peptide Antibiotics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Peptide Antibiotics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Peptide Antibiotics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Pfizer Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Merck & Co., Inc.
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. AbbVie Inc
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. GSK Group of Companies
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Sandoz International GmbH
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Xellia Pharmaceuticals
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. AuroMedics Pharma LLC
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. GlaxoSmithKline plc
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
    • 16.8.7. SWOT Analysis
  • 16.9. Teva Pharmaceutical Industries Ltd.
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
    • 16.9.7. SWOT Analysis
  • 16.10. Novartis AG
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis
    • 16.10.7. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer